Translate Bio Inc. (TBIO) and Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Comparison side by side

Translate Bio Inc. (NASDAQ:TBIO) and Osmotica Pharmaceuticals plc (NASDAQ:OSMT) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Translate Bio Inc. N/A 1308.74 108.27M -3.06 0.00
Osmotica Pharmaceuticals plc 274.34M 1.50 6.40M -0.13 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Translate Bio Inc. and Osmotica Pharmaceuticals plc.

Profitability

Table 2 provides us the return on assets, net margins and return on equity of both companies.

Net Margins Return on Equity Return on Assets
Translate Bio Inc. 0.00% 208.7% -52.9%
Osmotica Pharmaceuticals plc -2.33% 0% 0%

Liquidity

Translate Bio Inc.’s Current Ratio is 16.7 while its Quick Ratio is 16.7. On the competitive side is, Osmotica Pharmaceuticals plc which has a 1.3 Current Ratio and a 1.1 Quick Ratio. Translate Bio Inc. is better positioned to pay off short and long-term obligations compared to Osmotica Pharmaceuticals plc.

Analyst Ratings

The Ratings and Recommendations for Translate Bio Inc. and Osmotica Pharmaceuticals plc are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Translate Bio Inc. 0 0 2 3.00
Osmotica Pharmaceuticals plc 0 0 0 0.00

Translate Bio Inc.’s consensus target price is $23, while its potential upside is 233.33%.

Insider & Institutional Ownership

The shares of both Translate Bio Inc. and Osmotica Pharmaceuticals plc are owned by institutional investors at 49.9% and 37% respectively. About 19.6% of Translate Bio Inc.’s share are owned by insiders. Comparatively, insiders own roughly 41.8% of Osmotica Pharmaceuticals plc’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Translate Bio Inc. 17.7% 26.07% -26.26% 0% 0% -26.13%
Osmotica Pharmaceuticals plc -0.38% -11% 0% 0% 0% -3.68%

For the past year Osmotica Pharmaceuticals plc has weaker performance than Translate Bio Inc.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.